R S Foster
Overview
Explore the profile of R S Foster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
167
Citations
1254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Furuhama A, Kitazawa A, Yao J, Matos Dos Santos C, Rathman J, Yang C, et al.
SAR QSAR Environ Res
. 2023 Dec;
34(12):983-1001.
PMID: 38047445
Quantitative structure-activity relationship (QSAR) models are powerful in silico tools for predicting the mutagenicity of unstable compounds, impurities and metabolites that are difficult to examine using the Ames test. Ideally,...
2.
Thomas D, Kaimakliotis H, Rice K, Pereira J, Johnston P, Moore M, et al.
Urol Oncol
. 2018 Jun;
36(7):345.
PMID: 29880459
Background: Carcinoma in situ (CIS) is a poor prognostic finding in urothelial carcinoma. However, its significance in muscle-invasive urothelial carcinoma (MIUC) treated with neoadjuvant chemotherapy (NAC) is uncertain. We assessed...
3.
Albany C, Adra N, Snavely A, Cary C, Masterson T, Foster R, et al.
Ann Oncol
. 2017 Nov;
29(2):341-346.
PMID: 29140422
Background: To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of the International Germ Cell Cancer Collaborative Group (IGCCCG), and to compare our...
4.
5.
Albers P, Foster R, Voges G, Donohue J
Aktuelle Urol
. 2010 May;
41(3):201-10, 212.
PMID: 20486037
No abstract available.
6.
Ehrlich Y, Beck S, Ulbright T, Cheng L, Brames M, Andreoiu M, et al.
Ann Oncol
. 2010 Mar;
21(9):1846-1850.
PMID: 20231305
Background: The emergence of a primitive neuroectodermal tumor (PNET) within a germ-cell tumor (GCT) is rare. We assess the prognosis and response to treatment. Patients And Methods: Eighty-one patients were...
7.
Cheng L, Zhang S, Wang M, Davidson D, Morton M, Huang J, et al.
J Pathol
. 2007 Jul;
213(1):65-71.
PMID: 17634958
A residual retroperitoneal mass containing only fibrosis and necrosis is present in 40-52% of patients with advanced testicular germ cell tumours after chemotherapy. The biological nature and genetic characteristics of...
8.
Brandli D, Koch M, Foster R, Bihrle R, Gardner T
BJU Int
. 2003 Jun;
92(1):19-22; discussion 22-3.
PMID: 12823376
Objective: To examine our experience with radical prostatectomy (RP) in patients with a serum prostate-specific antigen (PSA) level of > 20 ng/mL (who are sometimes considered poor candidates for RP)...
9.
Foster R
Curr Treat Options Oncol
. 2002 Jun;
2(5):413-9.
PMID: 12057104
The treatment of low-stage testis cancer (defined as clinical stage I or low-volume clinical stage II disease) varies, depending on whether or not the orchiectomy specimen reveals seminoma or nonseminoma....
10.
Soergel T, Koch M, Foster R, Bihrle R, Wahle G, Gardner T, et al.
J Urol
. 2001 Nov;
166(6):2198-201.
PMID: 11696735
Purpose: We determined how prostate specific antigen (PSA) doubling time changed with time and whether an early measure of doubling time would accurately predict long-term PSA values and clinical outcome...